Thinn Pwint

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

Emma Dean, Mark R. Middleton, Thinn Pwint et al. · British Journal of Cancer · 2012 · 124 citations · Full text

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder

Christopher Blick, Peter Hall, Thinn Pwint et al. · Cancer · 2012 · 47 citations

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 43 citations · Full text

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Suzanne Leijen, Patricia M.M.B. Soetekouw, T.R. Jeffry Evans et al. · Cancer Chemotherapy and Pharmacology · 2011 · 41 citations · Full text

A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.

L Rhoda Molife, Martin Förster, Matthew Krebs et al. · Journal of Clinical Oncology · 2010 · 22 citations

Parp Inhibitor, Pharmacotherapy, Physiologically-based Pharmacokinetic Modeling +21